Log in

ContraFect News Headlines (NASDAQ:CFRX)

$8.81
-1.12 (-11.28 %)
(As of 02/28/2020 04:10 AM ET)
Today's Range
$8.60
Now: $8.81
$9.80
50-Day Range
$0.73
MA: $4.91
$11.30
52-Week Range
$2.69
Now: $8.81
$13.40
Volume250,642 shs
Average Volume295,473 shs
Market Capitalization$135.07 million
P/E Ratio22.03
Dividend YieldN/A
Beta0.68

Headlines

ContraFect (NASDAQ CFRX) News Headlines

Source:
DateHeadline
Zacks: Brokerages Expect ContraFect Corp (NASDAQ:CFRX) Will Post Earnings of -$0.92 Per ShareZacks: Brokerages Expect ContraFect Corp (NASDAQ:CFRX) Will Post Earnings of -$0.92 Per Share
www.americanbankingnews.com - February 27 at 5:50 PM
Short Interest in ContraFect Corp (NASDAQ:CFRX) Decreases By 64.1%Short Interest in ContraFect Corp (NASDAQ:CFRX) Decreases By 64.1%
www.americanbankingnews.com - February 26 at 11:02 PM
Form 8-K CONTRAFECT Corp For: Feb 24 - StreetInsider.comForm 8-K CONTRAFECT Corp For: Feb 24 - StreetInsider.com
www.streetinsider.com - February 25 at 8:25 AM
Health Care Sector Update for 02/24/2020: ENLV, CFRX, UTHR, JNJ, PFE, ABT, MRK, AMGN - NasdaqHealth Care Sector Update for 02/24/2020: ENLV, CFRX, UTHR, JNJ, PFE, ABT, MRK, AMGN - Nasdaq
www.nasdaq.com - February 24 at 7:41 PM
ContraFects (CFRX) Buy Rating Reaffirmed at Chardan CapitalContraFect's (CFRX) Buy Rating Reaffirmed at Chardan Capital
www.americanbankingnews.com - February 24 at 3:29 PM
BRIEF-Contrafect Announces FDAs Breakthrough Therapy Designation To Exebacase - ReutersBRIEF-Contrafect Announces FDA's Breakthrough Therapy Designation To Exebacase - Reuters
www.reuters.com - February 24 at 2:41 PM
ContraFect (CFRX) Gratned FDA Breakthrough Therapy Designation to Exebacase for the Treatment of MRSA Bacteremia, Including Right-Sided Endocarditis - StreetInsider.comContraFect (CFRX) Gratned FDA Breakthrough Therapy Designation to Exebacase for the Treatment of MRSA Bacteremia, Including Right-Sided Endocarditis - StreetInsider.com
www.streetinsider.com - February 24 at 8:37 AM
ContraFect +14% premarket on BTD tag for exebacase - Seeking AlphaContraFect +14% premarket on BTD tag for exebacase - Seeking Alpha
seekingalpha.com - February 24 at 8:37 AM
ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis - Yahoo FinanceContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis - Yahoo Finance
finance.yahoo.com - February 24 at 8:37 AM
ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided EndocarditisContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis
finance.yahoo.com - February 24 at 8:37 AM
BRIEF-ContraFect Says Regained Compliance With Minimum Bid Price Requirement Set Forth In Nasdaq Listing RuleBRIEF-ContraFect Says Regained Compliance With Minimum Bid Price Requirement Set Forth In Nasdaq Listing Rule
www.reuters.com - February 23 at 8:10 AM
BRIEF-ContraFect Says Regained Compliance With Minimum Bid Price Requirement Set Forth In Nasdaq Listing Rule - ReutersBRIEF-ContraFect Says Regained Compliance With Minimum Bid Price Requirement Set Forth In Nasdaq Listing Rule - Reuters
www.reuters.com - February 21 at 11:57 PM
CFRX: Updated Financials Following 1:10 Reverse Split; Phase 3 DISRUPT Trial Underway… - Yahoo FinanceCFRX: Updated Financials Following 1:10 Reverse Split; Phase 3 DISRUPT Trial Underway… - Yahoo Finance
finance.yahoo.com - February 18 at 6:14 PM
CFRX: Updated Financials Following 1:10 Reverse Split; Phase 3 DISRUPT Trial Underway…CFRX: Updated Financials Following 1:10 Reverse Split; Phase 3 DISRUPT Trial Underway…
finance.yahoo.com - February 18 at 6:13 PM
 ContraFect Corp (NASDAQ:CFRX) Given Average Rating of "Strong Buy" by Analysts ContraFect Corp (NASDAQ:CFRX) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - February 17 at 6:14 PM
CollPlant Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P. as Chairman of the Board of Directors - Yahoo FinanceCollPlant Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P. as Chairman of the Board of Directors - Yahoo Finance
finance.yahoo.com - February 10 at 6:35 PM
ContraFect: A Game-Changing Treatment For The Superbug MRSA - Seeking AlphaContraFect: A Game-Changing Treatment For The Superbug MRSA - Seeking Alpha
seekingalpha.com - February 10 at 6:35 PM
Zacks: Brokerages Anticipate ContraFect Corp (NASDAQ:CFRX) Will Announce Earnings of -$0.09 Per ShareZacks: Brokerages Anticipate ContraFect Corp (NASDAQ:CFRX) Will Announce Earnings of -$0.09 Per Share
www.americanbankingnews.com - February 5 at 6:46 AM
ContraFect Announces One-for-Ten Reverse Stock Split - Yahoo FinanceContraFect Announces One-for-Ten Reverse Stock Split - Yahoo Finance
finance.yahoo.com - February 4 at 6:20 PM
ContraFect Announces One-for-Ten Reverse Stock Split - GlobeNewswireContraFect Announces One-for-Ten Reverse Stock Split - GlobeNewswire
www.globenewswire.com - February 4 at 8:02 AM
ContraFect (CFRX) Announces 1-for-10 Reverse Stock Split - StreetInsider.comContraFect (CFRX) Announces 1-for-10 Reverse Stock Split - StreetInsider.com
www.streetinsider.com - February 4 at 8:02 AM
ContraFect Announces One-for-Ten Reverse Stock SplitContraFect Announces One-for-Ten Reverse Stock Split
finance.yahoo.com - February 4 at 8:02 AM
ContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology - GlobeNewswireContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology - GlobeNewswire
www.globenewswire.com - February 3 at 9:21 AM
ContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical MicrobiologyContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology
finance.yahoo.com - February 3 at 9:21 AM
ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - Yahoo FinanceContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - Yahoo Finance
finance.yahoo.com - January 27 at 1:15 PM
ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - GlobeNewswireContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - GlobeNewswire
www.globenewswire.com - January 27 at 7:37 AM
ContraFect to Present at 2020 ASM Biothreats - Yahoo FinanceContraFect to Present at 2020 ASM Biothreats - Yahoo Finance
finance.yahoo.com - January 22 at 5:40 PM
ContraFect to Present at 2020 ASM BiothreatsContraFect to Present at 2020 ASM Biothreats
finance.yahoo.com - January 22 at 5:40 PM
CFRX: Phase 3 DISRUPT Trial Underway… - Yahoo FinanceCFRX: Phase 3 DISRUPT Trial Underway… - Yahoo Finance
finance.yahoo.com - January 21 at 3:56 PM
CFRX: Phase 3 DISRUPT Trial Underway…CFRX: Phase 3 DISRUPT Trial Underway…
finance.yahoo.com - January 21 at 3:56 PM
ContraFect Corporation Is A Differentiated Infectious Disease Pick For 2020 - Seeking AlphaContraFect Corporation Is A Differentiated Infectious Disease Pick For 2020 - Seeking Alpha
seekingalpha.com - January 16 at 8:09 AM
ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections - Yahoo FinanceContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections - Yahoo Finance
finance.yahoo.com - January 13 at 8:22 PM
ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections - GlobeNewswireContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections - GlobeNewswire
www.globenewswire.com - January 13 at 8:39 AM
ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint InfectionsContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections
finance.yahoo.com - January 13 at 8:39 AM
ContraFect commences late-stage study of exebacase; shares up 8% premarket - Seeking AlphaContraFect commences late-stage study of exebacase; shares up 8% premarket - Seeking Alpha
seekingalpha.com - January 10 at 8:19 PM
ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis - Yahoo FinanceContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis - Yahoo Finance
finance.yahoo.com - January 10 at 3:16 PM
ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided EndocarditisContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
finance.yahoo.com - January 10 at 3:16 PM
January Is Often a Big Month for Biotech Mergers and Acquisitions - BarronsJanuary Is Often a Big Month for Biotech Mergers and Acquisitions - Barron's
www.barrons.com - January 8 at 4:44 PM
ContraFect to Present at Biotech Showcase 2020 Nasdaq:CFRX - GlobeNewswireContraFect to Present at Biotech Showcase 2020 Nasdaq:CFRX - GlobeNewswire
www.globenewswire.com - January 6 at 9:48 PM
Pfizer Bought Penny Biotech Stock ContraFect Just Before It Doubled - BarronsPfizer Bought Penny Biotech Stock ContraFect Just Before It Doubled - Barron's
www.barrons.com - January 4 at 7:58 AM
Pfizer Bought a Penny Biotech Stock Just Before It DoubledPfizer Bought a Penny Biotech Stock Just Before It Doubled
finance.yahoo.com - January 4 at 7:58 AM
Form PRE 14A CONTRAFECT Corp For: Jan 31 - StreetInsider.comForm PRE 14A CONTRAFECT Corp For: Jan 31 - StreetInsider.com
www.streetinsider.com - December 27 at 6:52 PM
Were Hedge Funds Right About Dumping ContraFect Corp (CFRX)? - Yahoo FinanceWere Hedge Funds Right About Dumping ContraFect Corp (CFRX)? - Yahoo Finance
finance.yahoo.com - December 20 at 1:54 PM
Were Hedge Funds Right About Dumping ContraFect Corp (CFRX)?Were Hedge Funds Right About Dumping ContraFect Corp (CFRX)?
finance.yahoo.com - December 20 at 1:54 PM
ContraFect (CFRX) Commences Pivotal Phase 3 DISRUPT Study of Exebacase as Treatment for Staph Aureus Bacteremia, Including Right-Sided Endocarditis - StreetInsider.comContraFect (CFRX) Commences Pivotal Phase 3 DISRUPT Study of Exebacase as Treatment for Staph Aureus Bacteremia, Including Right-Sided Endocarditis - StreetInsider.com
www.streetinsider.com - December 20 at 8:53 AM
ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis - GlobeNewswireContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis - GlobeNewswire
www.globenewswire.com - December 20 at 8:53 AM
ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided EndocarditisContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
finance.yahoo.com - December 20 at 8:53 AM
ContraFect (CFRX) Announces First Gram-negative Product Candidate CF-370, Direct Lytic Agent Targeting Pseudomonas aeruginosa - StreetInsider.comContraFect (CFRX) Announces First Gram-negative Product Candidate CF-370, Direct Lytic Agent Targeting Pseudomonas aeruginosa - StreetInsider.com
www.streetinsider.com - December 19 at 8:06 AM
ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa - GlobeNewswireContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa - GlobeNewswire
www.globenewswire.com - December 18 at 8:45 AM
ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosaContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa
finance.yahoo.com - December 18 at 8:45 AM
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel